Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EPS (Weighted Average and Diluted) (2021 - 2025)

Kiniksa Pharmaceuticals International's EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at $0.18 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 250.0% year-over-year to $0.18; the TTM value through Dec 2025 reached $0.75, up 222.95%, while the annual FY2025 figure was $0.75, 225.0% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.18 in Q4 2025 per KNSA's latest filing, down from $0.23 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.18 in Q3 2022 to a low of -$0.72 in Q1 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.03, with a median of -$0.15 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 822.73% in 2022, then crashed 133.33% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.52 in 2021, then surged by 109.62% to $0.05 in 2022, then soared by 620.0% to $0.36 in 2023, then crashed by 133.33% to -$0.12 in 2024, then soared by 250.0% to $0.18 in 2025.
  • Per Business Quant, the three most recent readings for KNSA's EPS (Weighted Average and Diluted) are $0.18 (Q4 2025), $0.23 (Q3 2025), and $0.23 (Q2 2025).